Ladero J M, González J F, Benítez J, Vargas E, Fernández M J, Baki W, Diaz-Rubio M
Department of Medicine, Complutense University, Madrid, Spain.
Cancer Res. 1991 Apr 15;51(8):2098-100.
Acetylator phenotype has been determined using sulfamethazine in 109 patients histologically diagnosed with colorectal carcinoma (resected in 74 patients by the time of the study) and in 96 age-matched controls. Fifty-five % of patients and 58.3% of controls were classified as slow acetylators (chi 2 = 0.11, not significant). No differences were observed in the distribution of acetylator phenotype when analyzing separately male and female, surgically treated and untreated, and colonic and rectal carcinoma patients. We conclude that acetylator polymorphism is not a genetic trait related to the risk of developing colorectal carcinoma in human beings.
采用磺胺二甲嘧啶对109例经组织学诊断为结肠直肠癌的患者（研究时74例已切除）及96例年龄匹配的对照者进行乙酰化代谢表型测定。55%的患者和58.3%的对照者被归类为慢乙酰化代谢者（χ² = 0.11，无显著性差异）。分别分析男性和女性、接受手术治疗和未接受手术治疗的患者以及结肠癌和直肠癌患者时，未观察到乙酰化代谢表型分布存在差异。我们得出结论，乙酰化代谢多态性并非与人类患结肠直肠癌风险相关的遗传特征。
